Claims for Patent: 8,535,681

Summary for Patent: 8,535,681

Title:	Sustained drug delivery system
Abstract:	A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components. Further, a method of treating the human body is disclosed. The method is for introducing into a human body a drug composition comprising a charged moiety coupled to a therapeutic compound. Introduction may be through injection. A method of manufacturing a drug composition comprising a charged moiety coupled to a therapeutic compound is also disclosed.
Inventor(s):	Farinas; Kathleen Cogan (Los Altos, CA), Chamow; Steven (San Mateo, CA)
Assignee:
Application Number:	13/124,654
Patent Claims:	1. A drug composition comprising: at least one positively charged moiety coupled to a therapeutic compound, wherein the positively charged moiety is a peptide with the amino acid sequence KGSKGSKGSKGSK (SEQ ID NO:1), KGKSKGKSK (SEQ ID NO:2), KGSKGSK (SEQ ID NO:3), or KGKSK (SEQ ID NO:4), and wherein the therapeutic compound is an anti-VEGF compound wherein the spacing of positive charges on the peptide is configured to interact with a spatial arrangement of negative charges on an anionic component to create an in situ depot for prolonged delivery of the anti-VEGF compound. 2. The drug composition of claim 1, comprising a spacer located at a coupling site between the therapeutic compound and the charged moiety. 3. The drug composition of claim 1, wherein the coupling is achieved using a stable covalent bond or a chemically labile covalent bond. 4. The drug composition of claim 1, wherein the anionic component is present in tissue. 5. The drug composition of claim 4, wherein the tissue is eye tissue. 6. The drug composition of claim 5, wherein the eye tissue is vitreous. 7. The drug composition of claim 1, wherein the anionic component is a glycosaminoglycan. 8. The drug composition of claim 7, wherein the glycosaminoglycan is hyaluronic acid. 9. The drug composition of claim 1, wherein the anti-VEGF compound is Bevacizumab. 10. The drug composition of claim 1, wherein the anti-VEGF compound is Ranibizumab. 11. The drug composition of claim 1, wherein the anti-VEGF compound is VEGF Trap. 12. A method of treating the human body comprising: introducing into a human body a drug composition comprising a charged moiety coupled to a therapeutic compound; wherein the charged moiety is configured to interact with at least one type of component of opposite charge in the human body to create an in situ depot for prolonged drug delivery. 13. The method of claim 12, wherein the drug composition is introduced into the eye. 14. The method of claim 12, wherein the drug composition is introduced into one or more location in the body selected from synovial fluid in a joint, brain, skin, cartilage, or a cancerous region.

Details for Patent 8,535,681

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2028-10-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2028-10-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2028-10-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2028-10-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2028-10-16